A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
3期
已完成
NCT06041217
| 适应症 | Overweight, Obesity |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Novo Nordisk A/S |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 242 人 |
|---|
| 干预（药物） | Semaglutide |
|---|
| 开始日期 | 2023年9月15日 |
|---|
| 完成日期 | 2025年4月2日 |
|---|
| 结果公布日 | 2026年5月18日 |
|---|
摘要
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.
Change in Body Weight (%)
Baseline (week 0), end of treatment (week 44) · Percentage change in body weight
| Semaglutide 2.4 mg | -12.2 ± 8.2 Percentage change in body weight |
|---|
| Placebo | -2.2 ± 5.4 Percentage change in body weight |
|---|
| p-value | <0.0001 |
|---|
| Treatment difference | -9.87 (95% CI -11.78–-7.96) |
|---|
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
At end of treatment (week 44) · Participants
| Semaglutide 2.4 mg | 128 Participants |
|---|
| Placebo | 19 Participants |
|---|
| Semaglutide 2.4 mg | 31 Participants |
|---|
| Placebo | 59 Participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 14.83 (95% CI 7.42–29.63) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。